Development of a Novel Test System for Screening for Antagonists of ErbB Receptors in Breast Cancer
Abstract
The focus of this project is to develop a system for screening for novel drugs and drug targets to inhibit the progression of breast cancer. Our approach capitalizes on recent findings in our laboratory that should allow new types of screens for drugs. These screens should enable the identification of drugs that arrest the growth of breast cancer cells as well as the identification of new drug targets. Specifically, certain growth factor receptors will be targeted that are known to be present in abundance on the surface of breast cancer cells. These receptors have been designated as the ErbB family of receptors. Cancers expressing an abundance of one of these receptors, the ErbB2 receptor, have been shown to be resistant to conventional therapy. Very recently a drug that targets ErbB2 directly has been found to increase patient survival in a phase III clinical trial. The identification of additional drugs or small molecules that target this family of receptors and impair their function should greatly enhance our ability to successfully treat patients with this form of cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2002
- Accession Number
- ADA407285
Entities
People
- Helen M. Blau
Organizations
- Stanford University